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Abstract
Background: Transmitted HIV-1 clade B or C R5 viruses have been reported to infect macrophages inefficiently,
while other studies have described R5 viruses in late disease with either an enhanced macrophage-tropism or
carrying envelopes with an increased positive charge and fitness. In contrast, our previous data suggested that
viruses carrying non-macrophage-tropic R5 envelopes were still predominant in immune tissue of AIDS patients. To
further investigate the tropism and charge of HIV-1 viruses in late disease, we evaluated the properties of HIV-1
envelopes amplified from immune and brain tissues of AIDS patients with neurological complications.
Results: Almost all envelopes amplified were R5. There was clear compartmentalization of envelope sequences for
four of the five subjects. However, strong compartmentalization of macrophage-tropism in brain was observed
even when brain and immune tissue envelope sequences were not segregated. R5 envelopes from immune tissue
of four subjects carried a higher positive charge compared to brain envelopes. We also confirm a significant
correlation between macrophage tropism and sensitivity to soluble CD4, a weak association with sensitivity to the
CD4 binding site antibody, b12, but no clear relationship with maraviroc sensitivity.
Conclusions: Our study shows that non-macrophage-tropic R5 envelopes carrying gp120s with an increased
positive charge were predominant in immune tissue in late disease. However, highly macrophage-tropic variants
with lower charged gp120s were nearly universal in the brain. These results are consistent with HIV-1 R5 envelopes
evolving gp120s with an increased positive charge in immune tissue or sites outside the brain that likely reflect an
adaptation for increased replication or fitness for CD4+ T-cells. Our data are consistent with the presence of
powerful pressures in brain and in immune tissues selecting for R5 envelopes with very different properties; high
macrophage-tropism, sCD4 sensitivity and low positive charge in brain and non-macrophage-tropism, sCD4
resistance and high positive charge in immune tissue.
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Background
Human immunodeficiency virus type 1 requires interac-
tions with CD4 and either CCR5 or CXCR4 coreceptors
to trigger fusion of viral and cellular membranes and
entry into cells. CCR5-using (R5) viruses are mainly
transmitted and individuals homozygous for a defective
CCR5 gene (Δ32 CCR5) are substantially protected from
infection [1]. Recent studies of clade B and clade C
transmission events have shown that the transmitted R5
viruses are unable to efficiently infect macrophages,
whether transmission is sexual [2,3] or via mother-to-
child [4]. In late disease, CXCR4-using (X4) variants can
be isolated from up to 50% of AIDS patients and are
associated with a more rapid loss of CD4
+ T-cells and
faster disease progression [5-8]. However, whether R5
viruses evolve distinct properties that impact on patho-
genesis is poorly understood. R5 viruses with an
enhanced macrophage-tropism were isolated from adult
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develop CXCR4-using variants. However, our previous
data indicated that viruses carrying non-macrophage-
tropic R5 envelopes were present in immune tissue
(lymph nodes) in late disease, even in subjects with neu-
rological complications who carried highly macrophage-
tropic variants in brain tissue [12,13]. Finally, other
groups reported that envelopes with an increased posi-
tive charge, fitness and reduced sensitivity to CCR5 inhi-
bitors [14-17] evolve in late disease. Whether increased
macrophage-tropism and envelope charge are separate
or related properties has not been extensively
researched, although in a preliminary study, we did not
detect a correlation [18]. The current study was
designed to investigate the relationship between macro-
phage-tropism and gp120 charge for HIV-1 R5 envel-
opes present in immune and brain tissue of AIDS
patients with neurological issues.
Untreated HIV-1+individuals frequently suffer from
HIV associated neurocognitive disorders, which are char-
acterized by sensory neuropathy, sensory myelopathy and
eventually dementia. The most severe dementias occur in
about 30% of AIDS patients. The mechanisms that cause
dementia are unclear but likely involve disruption of nor-
mal neurological functions by toxic factors that are upre-
gulated either as a direct result of HIV replication or
indirectly as a consequence of inflammatory processes
[19-21]. Even in the era of highly effective anti-retroviral
therapies, milder neurocognitive impairments persist
[ 2 2 , 2 3 ] ,w h i l et h em o r es e v e r en e u r o c o g n i t i v ed i s o r d e r s
are still apparent in subjects who fail therapy [24].
The brain is colonized early after infection [25]. How-
ever, proviral DNA is difficult to detect in brain tissue dur-
ing the asymptomatic phase [26-29]. Mechanisms of entry
into the brain are unclear, although the virus must pene-
trate the blood brain barrier (BBB) or enter via the choroid
plexus and cerebral spinal fluid (CSF). A ‘trojan horse’
mechanism of entry is favored whereby infected mono-
cytes carry the virus through the BBB [30]. In support of
this, HIV env sequences in deep white matter were
reported to be more closely related to env sequences in
blood monocytes than sequences from other tissues
[31,32], although only a single individual was studied.
In situ hybridization and immunohistochemistry have
detected HIV infection and accumulation in cells sur-
rounding blood capillaries including CD14
+ cells [33-35].
These CD4
+ CCR5
+ perivascular macrophages are a major
reservoir of HIV-1 in the brain [19,36-38]. A hallmark of
HIV-associated neuropathology is the presence of multi-
nucleated giant cells (MNGCs) in brain tissue [19,39].
M N G C se x p r e s sC D 6 8a n da r eb e l i e v e dt or e s u l t
from HIV induced fusion of infected and uninfected peri-
vascular macrophages [40]. Resident microglia (monocyte/
macrophage lineage) are also infected in humans
[36,37,41] and support HIV replication when cultured in
vitro [19]. The number of activated monocytes in blood
was reported to correlate with AIDS dementia [42], and it
is likely that the brain is reseeded by infected, activated
monocytes that enter the brain in late disease [32].
Many studies have shown that HIV-1 sequences are fre-
quently compartmentalized in the brain and are distinct
from sequences from blood or immune tissue [43-49]. A
relatively small number of highly macrophage-tropic R5
virus isolates made from brain tissue have been described
[50,51]. Fewer studies have compared the phenotypes of
envelopes derived by PCR without culture from these
compartments. As discussed above, we reported that
envelopes amplified from brain tissue were predominantly
highly tropic for macrophages while those from other sites
including blood, plasma, lymph node and spleen were pre-
dominantly non-macrophage-tropic despite uniformly
using CCR5 and not CXCR4 [12,52]. The only other study
to investigate the tropism of PCR amplified envelopes also
described a wide variation in macrophage-tropism of R5
envelopes but failed to demonstrate a clear association of
mac-tropism with brain envelopes compared to those
from lymphoid tissue [53]. Furthermore, a potential role
for CXCR4-using viruses in the brain has also been pro-
posed [50,51,54,55]. It should also be emphasized that
these earlier studies investigating the phenotypes of envel-
opes amplified from brain tissue studied relatively few
envelopes from only a few individuals [12,13,53].
Here, we endeavored to evaluate the phenotypes of a
large number of envelopes amplified by PCR from the
brain and the immune tissue. We present a detailed inves-
tigation of 183 envelope clones amplified from brain,
spleen and lymph node tissue of five subjects including
four new subjects who died with HIV associated dementia.
W es h o wt h a tH I V - 1R 5e n v e l opes carrying gp120s with
an increased positive charge were present in immune tis-
sue and had evolved independently from highly macro-
phage-tropic variants with low charge gp120s in the brain.
We also show that independent evolutionary pathways to
macrophage-tropism are present in immune tissue. In
summary, our data are consistent with the presence of
powerful pressures in brain and in immune tissue selecting
for (or against) R5 envelopes that are highly macrophage-
tropic or that carry an increased gp120 charge respectively.
Our study provides important new insights into the evolu-
tion of HIV-1 R5 envelopes with very distinct properties at
different sites in the body and driven by powerful tissue
specific evolutionary pressures.
Results
Compartmentalization of HIV-1 envelope sequences from
brain, lymph node and spleen tissue
We first investigated the compartmentalization of envel-
ope sequences (n = 183) amplified from proviral or
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conditions (Table 1). Circular episomal DNA has been
reported to be labile in T-cells and associated with
ongoing replication [56], although this is controversial
[57]. A further report suggested that circular DNA forms
were more stable in macrophages [58]. Envelope gp160
sequences were amplified from DNA extracted from
frontal lobe tissue for all subjects, from the cerebellum
for subject 7766 and occipital lobe for CA110. Envelopes
were also amplified from the spleen of four subjects and
from the lymph node of two including the fifth subject
(NA20). Phylogenetic trees were produced using maxi-
mum likelihood methods via MEGA version 5. All envel-
opes amplified clustered with standard clade B envelopes
and not with envelopes from other clades (data not
shown). Trees presented on Figure 1 were rooted with
t h r e ec l a d eBe n v e l o p es e q u e n c e s .E n v e l o p es e q u e n c e s
for each subject segregated separately, were distinct from
the three clade B reference sequences and did not segre-
gate with any on the HIV sequence database http://www.
hiv.lanl.gov/content/sequence/HIV/mainpage.html. For
four subjects, brain envelopes were distinct from those
from spleen (7766, CA110 and 6568) or lymph node
(CA110 and NA20). Envelopes from the fifth subject
(10017) were more interspersed. Envelopes amplified
from circular DNA forms did not segregate separately
from proviral DNA, regardless of tissue origin.
Almost all envelopes amplified were R5
All envelopes were screened for functionality by testing
whether env+ pseudovirions conferred infection of HeLa
TZM-bl cells, which express recombinant CD4 and CCR5
along with endogenous CXCR4. 56.9% of envelopes con-
ferred high levels of infectivity for HeLa TZM-bl cells
regardless of whether they were amplified from frontal
lobe, spleen or lymph node. In contrast, envelopes ampli-
fied from the cerebellum of subject 7766 were not func-
tional in pseudovirion assays. Some of the non-functional
envelope carried premature stop codons. However, the
majority had open reading frames and their lack of func-
tion was unclear.
CXCR4-use was tested on HeLa HIJ cells, which
express CD4 and CXCR4 but not CCR5. Only envelope
22-15-107 (from the spleen of subject 10017) conferred
low levels of HIJ infection likely indicating CXCR4-use.
Thus, nearly all envelopes were R5 even though all the
subjects under investigation had AIDS. Furthermore, all
envelopes except for 22-15-107 and 14-10-73 (non-func-
tional) were designated as R5 using the Web based
PSSM program http://indra.mullins.microbiol.washing-
ton.edu/webpssm/ and carried overall positive charges
of +1-5 (total of R and K residues minus total of E and
D residues). Envelopes 22-15-107 and 14-10-73 (non-
functional) carried a higher V3 charge (+7) consistent
with CXCR4-use. These conclusions are further sup-
ported by inhibition data on HeLa TZM-bl cells for
maraviroc (see below).
Macrophage-tropism of envelopes from brain, spleen and
lymph node tissue
We next investigated whether the ability of envelopes to
infect primary macrophages was compartmentalized
between the brain and immune tissue. We cannot be cer-
tain that envelopes amplified from brain tissue were
derived from infected macrophages since astrocytes have
also been reported to be infected [38,40,59-63]. Never-
theless, nearly all envelopes amplified from brain tissues
conferred highly efficient infection of macrophages. In
contrast, envelopes amplified from spleen or lymph node
varied in macrophage-tropism from background levels up
to modest levels of infection, and for a minority of envel-
opes, highly efficient infection (Figure 2). Thus, highly
efficient macrophage infection was observed for subject
10017 spleen envelopes, 20-12-82 and 9-8-57, which
clustered phylogenetically among a group of brain-
derived envelopes (and along with three further spleen
envelopes that were non-functional). However, for most
subjects, envelopes from spleen or lymph node (that seg-
regated separately from brain env sequences) showed a
gradation in their capacity to infect macrophages ranging
from background infection to modestly efficient levels,
consistent with an independent evolutionary pathway to
macrophage-tropism in immune tissue. In addition, the
lymph node envelope 23-14-2 from NA20 conferred high
levels of macrophage infection (similar to most brain
envelopes), while clustering phylogenetically (Figure 1)
Table 1 Characteristics of HIV-1+ subjects studied
Patient No. Collection Year Brain Bank Disease status CD4 count Viral Load* Therapy history
7766 1999 NNTC AIDS, HAD, HIVE 43 1,843 3TC, ABC, EFV, D4T, DDI, IDV, NFV, ZDV
6568 2001 NNTC AIDS, HAD, HIVE 77 > 750,000 3TC, ABC, D4T, DDC, DDI, EFV, IDV, NFV, NVP, ZDV
CA110 1999 UCSD AIDS, HAD, HIVE 21 198,957 No use reported
10017 1999 Mt. Sinai AIDS, HIVE, IVDU 7 389,120 3TC, D4T, SQV, ZDV
NA20 1993 Edinburgh Hemophiliac** 4 – No use reported
*Last available record prior to death
**Mild cognitive impairment, sparse giant cell encephalitis, cerebral toxoplasmosis. Status = hemophiliac
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cient macrophage infection (Figure 2). This observation
suggests that 23-14-2 evolved efficient macrophage infec-
tion independently from those in the brain. However,
further analyses indicated that 23-14-2 is a recombinant
between spleen and brain envelopes (data not shown).
A minority of brain-derived envelopes clustered closely
with those from spleen; 20-15-33 (subject 7766) and 51-4-
4 (subject CA110). Unfortunately, the 7766 envelope was
not functional. However, 51-4-4 conferred a non-macro-
phage-tropic phenotype similar to spleen and lymph node
envelopes, suggesting that it could have been derived from
blood in brain tissue capillaries.
Immune tissue envelopes carry a higher overall positive
charge in V1-V2 and V1-V5 regions
Previous studies reported two distinct and emerging phe-
notypes for primary R5 viruses isolated from blood in late
disease. First, R5 isolates carrying a higher overall positive
charge for the V1-V5 region were reported to carry
increased fitness and decreased sensitivity to CCR5 ligands
[14-17]. These properties were hypothesized to result in
enhanced envelope interactions with CCR5 and increased
replication in T-cells [14-17] including populations
expressing lower CCR5 levels [64]. Second, several studies
reported on the isolation of R5 isolates from blood of
adult and pediatric AIDS patients that conferred an
Figure 1 Phylogenetic analysis (MEGA 5) of HIV-1 envelope nucleotide sequences amplified from brain and immune tissue.T i g h t
compartmentalization of brain and immune tissue envelope sequences was observed for subjects CA110, 6568, 7766 and NA20. Envelope
compartmentalization was less clear for subject 10017. Numbers at branch points represent bootstrap values.
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significant differences in the overall positive charge of V1-
V5 and V1-V2 amino acids for 4 of the 5 subjects (Figure
3A, B). Brain-derived envelopes from these four subjects
carried a lower overall charge compared to those from
immune tissue (Table 2). For the fifth subject (NA20),
there were insufficient brain envelopes to undertake a rea-
sonable comparison. These observations show for the first
time that these distinct envelope characteristics arise inde-
pendently. R5 variants with increased gp120 charge appear
to evolve in immune tissue while highly mac-tropic var-
iants predominantly emerge in the brain and possibly
other non-immune tissues where macrophages are the
main targets for infection.
Brain and immune tissue envelopes sometimes differ in
length and potential N-linked glycosylation sites
There were significant differences in V1-V5 length between
brain and immune tissue envelopes for subjects 7766, 6568
and NA20 but not for other subjects (Figure 4A, Table 2).
Figure 2 Compartmentalized macrophage infectivity for brain and immune tissue envelopes. Nearly all envelopes amplified from brain
tissue efficiently infected primary macrophage cultures. In contrast, envelopes from immune tissue varied in the capacity to infect macrophages
with infection ranging from background levels to highly efficient infection for a small minority. Infectivity is presented as FFU/ml and was
derived from titers averaged from at least two assays using macrophage prepared from different donors.
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Figure 3 Overall positive charge of HIV-1 V1-V2 and V1-V5 regions of envelopes amplified from brain and immune tissue. Immune
tissue envelopes from four of five subjects carry a significantly higher positive charge compared to corresponding envelopes from brain. A-B:
Overall positive charge of V1-V5 (A) and V1-V2 (B) amino acid sequences. All amplified envelopes shown in Figure 1 were included in this
analysis.
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and 7766 brain and spleen envelopes were reversed, while
only three NA20 brain envelopes were available for testing.
Similarly, no clear pattern between V1-V2 length and
brain, immune tissue or macrophage infectivity emerged
(Table 2).
There were some differences in the number of poten-
tial N-linked glycosylation sites (PNGSs) between brain
and immune tissue envelopes (Figure 4B, Table 2). For
subjects CA110, 7766 and 6568 those differences were
of significance. Curiously, for these subjects, the brain
derived envelopes carried a slightly higher average num-
ber of PNGSs compared to LN/spleen envelopes.
These observations do not show consistent relation-
ships between either gp120 length or PNGSs sites on
gp120 with non-macrophage-tropic or macrophage-tro-
pic phenotypes of R5 envelopes late in disease.
Envelope signatures for brain and macrophage-tropism
Dunfee et al. reported that an asparagine at residue 283
(in the C2 part of the CD4bs; not a glycosylation site)
was present in 41% envelopes amplified from brain tissue
of subjects with HAD but only in 8% from non-HAD
subjects [65]. N283 confers an increased affinity for CD4
[65] and enhances macrophage infectivity [12,65]. Con-
sistent with Dunfee’s observations, all the envelopes from
NA20 brain tissue contained N283, compared with only
14.3% of those from LN (Table 2). However, all the envel-
opes amplified from subjects CA110 and 7766 carried
N283, while none of those from 6568 and 10017 did. Yet
for these four subjects, brain derived envelopes were con-
sistently more macrophage-tropic compared to those
from spleen.
Several studies have implicated the glycan at residue 386
in the protection of the CD4bs [66,67] and macrophage
infection [67,68]. For subject 6568, all envelopes from
spleen carried a PNGS at N386, which was absent in
envelopes from brain tissue. For the other four subjects,
all envelopes from brain and spleen tissue carried the
PNGS at N386.
Together these results show that N283 and the PNGS
at N386 sometimes associate with macrophage-tropism
and a brain origin. However, this is clearly not a univer-
sal relationship.
Sensitivity of envelopes to the CD4bs mab, b12, soluble
CD4 and maraviroc
We previously reported a significant correlation between
macrophage tropism and sensitivity to sCD4 inhibition for
a large panel of envelopes derived from brain and immune
tissues as well as from blood and semen [52]. However,
there was no significant correlation between macrophage
infection and sensitivity to CCR5 antagonists, TAK779
and SCH350581, even though for two subjects, envelopes
from brain were significantly more sensitive than those
from lymph node [52]. In this previous study, we also
observed a trend between macrophage-tropism and sensi-
tivity to the CD4bs mab, b12, although it did not reach
significance. These observations support an enhanced
interaction between the envelope and CD4 (but not
CCR5) for highly macrophage-tropic R5 variants. In con-
trast to our data, Dunfee et al. reported a significant asso-
ciation between enhanced macrophage-tropism in the
brain and b12 sensitivity but did not find a relationship
with sCD4 sensitivity [69]. To further investigate envelope
interactions with CD4 and CCR5, we selected a subset of
32 envelopes from brain and immune tissue of the five
subjects (Table 3) along with control non-macrophage-
tropic JR-CSF and macrophage-tropic JR-FL envelopes
and tested their sensitivity to b12, sCD4 and maraviroc
Table 2 Characteristics of envelopes amplified from brain and immune tissue
Subject Tissue N° of
Amplicons
Average length (amino acids) Average Overall Positive Charge N° of CHO
V1-V5*
Presence of
N283 (%)
Presence of
N386 (%)
V1-V2 V1-V5 V3 V1-V2 V1-V5 V3
CA110 FL 10 68.7 337.8 35 -0.9 5.3 3 22.7 100 100
OC 7 69 338 35 -1 8.7 3 21 100 100
SP 30 66.9 338.4 35 0.6 10.7 3.5 21.2 100 100
LN 16 65.9 338 35 0.3 10.2 3.6 20.5 100 100
7766 FL 19 67.1 342.8 35 -2 5.5 1.8 18.8 100 100
CB 2 68 344 35 -1.5 7.5 2 19 100 100
SP 18 67.4 341.6 35 0 9.8 1.9 18.3 100 100
6568 FL 6 65 335 34 -1.7 2.5 2.8 17.7 0 0
SP 31 68.1 338.4 35 0.9 7.6 1.1 15.9 0 100
10017 FL 17 72.6 346.5 35 -1.1 8.2 4 20.9 0 100
SP 10 73.7 346.6 35 0.1 9.9 4.7 21.3 0 100
NA20 FL 3 70 346.7 35 1.7 7 3.3 20 100 100
LN 14 73.4 354.4 35 2.8 7.8 3.8 20.2 14.3 100
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include representatives from each subject that covered the
full range of macrophage infectivity observed in LN/
spleen. Brain envelopes included were all highly macro-
phage-tropic except for FL19-49-26, which did not infect
macrophages.
Our new data confirm that brain-derived envelopes
were significantly more sensitive to sCD4 inhibition
compared to those from LN/spleen (Figure 5A). How-
ever, we did not detect significant differences between
brain and LN/spleen envelopes for maraviroc or b12
sensitivity (Figure 5A).
We next compared maraviroc, sCD4 and b12 sensitivity
to macrophage infectivity (Figure 5B). As we previously
reported [52], there was a highly significant correlation
between macrophage infectivity and sCD4 sensitivity, but
not with maraviroc. A weak correlation with b12 was
detected, whereas previously only a trend was noted [52].
In addition, all envelopes tested (except for the CXCR4-
using 22-15-107) were completely inhibited by maraviroc
(data not shown), i.e. there was no reduction in the level
of maximal inhibition that has been associated with use
of drug occupied CCR5 [70] or the use of an additional
alternative coreceptor.
It needs to be emphasized that the compartmentaliza-
tion of brain and immune tissue envelopes can lead to
the segregation of different phenotypes that reflect the
properties of the founding viruses, rather than a specific
adaptation to the tissue. To avoid this possibility, we
also evaluated whether the variation in macrophage
infectivity observed solely among LN/spleen envelopes
correlated with sensitivity to sCD4, b12 or maraviroc.
The p values obtained for each inhibitor were similar to
those obtained using the full panel of brain and immune
tissue envelopes. Our results therefore confirm a strong
correlation between macrophage infectivity and sCD4
Figure 4 Brain and immune tissue V1-V5 gp120 do not significantly differ in length (A) and or extent of N-linked glycosylation sites
(B). All amplified envelopes shown in Figure 1 were included in this analysis.
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(Figure 5C).
Discussion
Our data show for the first time that macrophage-tropism
and increased envelope charge among HIV-1 R5 envelopes
evolve independently in brain and immune tissue. We also
confirm and greatly extend our previous studies that had
indicated the compartmentalization of envelope phenotype
with macrophage-tropic envelopes in brain tissue and a
predominance of non-macrophage-tropic envelopes in
immune tissue and plasma [12,13]. The predominance of
charged envelopes in immune tissue is consistent with an
adaptation for replication in CD4+ T-cells and perhaps
colonization of T-cells expressing lower levels of CCR5
late in disease [64]. We are currently investigating these
possibilities.
Here, envelope sequences from brain and spleen (or
lymph node) derived envelopes were compartmentalized
for 4 of 5 subjects. Subject 10017 was clearly an excep-
tion, where several of the spleen envelopes clustered with
those from frontal lobe. Nevertheless, for all subjects
(including 10017), macrophage-tropism was consistently
highly compartmentalized to brain tissue. In contrast, the
vast majority of envelopes from spleen or lymph node
were substantially less macrophage-tropic, varying from
background levels of infectivity to moderate infection
with strong macrophage infection conferred by only a
minority of envelopes. The consistent compartmentaliza-
tion of envelope phenotype (even in the absence of
sequence segregation) is consistent with the presence of
strong environmental pressures in the brain and immune
tissues selecting for highly macrophage-tropic and non-
macrophage-tropic envelopes respectively.
A small number of highly macrophage-tropic envelopes
were detected in immune tissue. However, we do not have
categorical evidence that they evolved there. The highly
macrophage-tropic envelopes from the spleen of subject
10017 clustered among brain-derived envelopes and have
not originated independently. The highly macrophage-tro-
pic envelope 23-14-2 from subject NA20 LN clustered
with those in lymph node. Our initial interpretation was
that macrophage-tropism of this envelope may have
evolved independently from those in brain. However, sub-
sequent analyses via Simplot revealed that this envelope
was a recombinant and carried sequences between the V1
and V3 loops more closely related to those in brain
derived envelopes (data not shown). This observation adds
further support to Brown’s recent report on intercompart-
ment recombination modulating tropism and contributing
to diversity and with affects on tropism [71]. For subjects
7766, 6568 and CA110, a clear gradation of macrophage-
tropism was observed in immune tissue with the most
macrophage-tropic envs conferring moderate levels of
infectivity (although less than the highly mac-tropic brain
envelopes). The range of macrophage infectivity in
immune tissue of these subjects represents clearer evi-
dence of an independent route to macrophage-tropism
compared to brain envelopes. Only very few non-macro-
phage-tropic envelopes were amplified from the brain tis-
sue samples. These included 51-4-4 from subject CA110
frontal lobe and 31-2-9 from 10017 frontal lobe. These
envelopes may have been amplified from T-cells circulat-
ing in brain blood capillaries.
Envelope determinants previously reported to be asso-
ciated with macrophage-tropism include (1) N283 in the
CD4bs, which confers an increased affinity for CD4 [65]
and enhances macrophage infectivity [12,65]. (2) The
loss of an N-linked glycosylation site at residue 386
Table 3 Brain and immune tissue envelopes selected for
inhibitor analyses
Subject Tissue Envelop Macrophage infectivity
6568 Frontal lobe FL 11-1-249 +++
FL5-47-202 +++
Spleen SP 12-23-41 +++
SP 12-24-49 -
SP 6-22-81 -
SP 12-14-25 -
SP 6-25-105 -
10017 Frontal lobe FL24-11-83 +++
FL27-1-1 +++
Spleen SP10-9-65
SP22-15-107
SP9-8-57
SP20-12-82
7766 Frontal lobe FL 19-49-26 +++
FL 19-54-50 +++
FL 19-56-66 -
Spleen SP 13-12-145 -
SP 13-33-41 -
SP 15-59–96 +
CA100 Frontal lobe FL 58-13-15 ++
FL 58-30- 92 +++
FL 56-33-33 +++
Spleen SP 53-6-122 -
SP 52-20-75 -
SP 52-16-50 -
SP 14-33-34 ++
NA20 Frontal lobe B59 +++
B501-26 +++
Spleen LN8 -
LN10 -
LN14 -
LN23-14-2 +++
JR Frontal lobe JRFL +++
Spleen JRCSF -
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However, none of these determinants fully explain the
macrophage-tropism of the envelopes studied here. Only
for subject NA20, did N283 segregate predominantly
with brain envelopes. Curiously, while all envelopes
amplified from subjects CA110 and 7766 carried N283,
none of those from 6568 and 10017 did. Yet for these
four subjects, brain derived envelopes were consistent in
conferring substantially higher levels of macrophage
infection compared to those from spleen regardless of
the presence or absence of N283. All eight brain-derived
envelopes from subject 6568 lacked N386 consistent
with the reported association. However, all other envel-
opes amplified in this study contained N386, indicating
that its loss is subject dependent. A recent study
describing highly macrophage-tropic envelopes amplified
Figure 5 Sensitivity of brain and immune tissue envelopes to inhibition by soluble CD4, the CD4bs mab, b12 and the CCR5
antagonist maraviroc: The impact of macrophage tropism. A panel of 32 envelopes that represented the full range of macrophage-tropism
observed for LN/spleen envelopes and included highly macrophage-tropic envelopes from the brain was tested for their sensitivity to sCD4, b12
and maraviroc using env+ pseudovirions. A. Brain envelopes were significantly more sensitive to sCD4 compared to those from immune tissues,
but are not significantly more sensitive to maraviroc or the CD4bs mab, b12. B. Soluble CD4 sensitivity correlates with macrophage infectivity
and is highly significant. There is a weaker correlation between b12 sensitivity and macrophage infection. Control envelopes JR-FL (mac-tropic)
and JR-CSF (non-mac-tropic) are depicted as green and red spots respectively. C. Even when just LN/spleen envelopes are analyzed, there is a
strong correlation between macrophage infection and sCD4 sensitivity as well as a weaker association with b12. This latter observation rules out
the possibility that brain or LN/spleen founder effects affect the correlations shown.
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tropism [73]. Further investigation is needed to provide
a clearer view of the envelope changes in structure and
function that contribute to macrophage-tropism.
Finally, studies from other groups have implicated a
more efficient or altered engagement with CCR5 for
macrophage-tropic R5 envelopes including those in the
brain [51,74]. However, this has not been evident in our
studies using maraviroc here or other CCR5 antagonists
in previous studies [52]. Nor have we detected consis-
tent differences in infectivity assays using HeLa cell lines
expressing different levels of CCR5 [12,13]. Nevertheless,
further experiments are needed to evaluate whether
macrophage-tropic R5 envelopes (described here) exploit
distinct regions of CCR5.
HIV-1 R5 viruses that are non-macrophage-tropic are
preferentially transmitted [1-4,75,76]. Data presented
here indicate that they still predominate in immune tis-
sue even in late disease. However, increased T-cell trop-
ism (either via CXCR4-use or via retention of CCR5-use
[14-17]) and enhanced macrophage-tropism [9-11] are
likely to be independent indicators perhaps associated
with distinct pathogenic outcomes.
Conclusions
We show that highly macrophage-tropic, low positive
charge envelopes can be detected in brain tissue of AIDS
patients suffering from severe neurological disease. These
highly macrophage-tropic envelopes contrast sharply with
those present in immune tissue that mainly confer ineffi-
cient macrophage infection. These latter envelopes carry a
higher positive charge that was previously associated with
increased T-cell tropism. Strikingly, these distinct pheno-
types were evident for subject 10017, even though
sequences for this subject were closely related and not
clearly compartmentalized. Our data are consistent with
the presence of powerful selective environments in
immune and brain tissue that select for R5 virus variants
with very different characteristics and tropism properties.
Methods
HIV-1+ subjects
Brain frontal and occipital lobes, cerebellum, together with
spleen and LN samples were obtained at autopsy and kept
frozen at -80°C. Tissue samples were provided by the
National NeuroAIDS Tissue Consortium (NNTC) and by
the University of Edinburgh Brain Bank. HIV-1 envelopes
described here were amplified from subjects 7766, 6568,
CA110, 10017 and NA20; heterosexual patients with HIV
associated dementia (HAD), H I Ve n c e p h a l i t i s( H I V E )o r
cognitive impairment all of whom progressed to AIDS and
died. Table 1 lists the five patients included for this study.
Samples from three subjects provided by the NNTC are
from patients treated extensively by HAART (7766, 6568
and 10017), while the fourth (CA110) had no reported
use. NA20 was described previously and was a subject
from before the HAART era [12,13]. We have increased
the number of functional envelopes amplified from this
subject.
Nucleic acid extraction and PCR amplification of env from
single molecule templates
Total DNA was purified from tissues using the QIAamp
DNA Mini kit (Qiagen), according to the manufacturer’s
instructions. DNA was eluted in nuclease-free water and
frozen immediately at -20°C for storage until analysis.
Sequences covering rev and env genes were amplified by
nested PCR from proviral and circular (episomal) forms of
viral DNA present in brain and spleen or LN tissue. The
presence of rev in cis upstream from envelope is impor-
tant for efficient envelope expression and production of
high titer env+ pseudovirions. PCRs were carried out
using serially diluted tissue DNA samples so that envel-
opes subsequently cloned were derived from single gen-
omes when 30% or less of PCR reactions were positive.
PCRs used high fidelity DNA polymerases (Platinum
®Taq
DNA Polymerase; Invitrogen Inc., or Phusion™ DNA
Polymerase; Finnzymes Inc.). PCRs were set up as
described previously [12] using the following primers. For
proviral amplification, outer primers were RevenvA (5’-
TAGAGCCCTGGAAGCATCCAGGAAG-3’)a n dE n v N
(5’-CTGCCAATCAGGGAAGTAGCCTTGTGT-3’).
Outer primers for episomal DNA amplification were
RevenvA and LAI (5’-GCGCTTCAGCAAGCCGAGT
CCT-3’) [56]. The inner primers were the same for both
proviral and episomal rev-env amplification as follows;
RevenvBTOPO (5’-CACCTAGGCATCTCCTATGG-
CAGGAAGAAG-3’) and Env-lo (5’-GTTTCTTCCA
GTCCCCCCTTTTCTTTTAAAAAG-3’; [77]). The PCR
products in positive wells at endpoint dilutions were puri-
fied from a 0.8% crystal violet stained agarose gel using a
QIAquick Gel Extraction Kit (Qiagen).
All envelopes from subjects CA110, 7766, 6568 and
10017 were amplified and cloned using limiting dilution
protocols [2,78]. NA20 envelopes, (including previously
described B59, B76, B501, LN8, LN10, LN14 and LN16
[12,13] and newly amplified envelopes, (23-14-2, 23-14-3,
23-14-4, 23-14-9, 23-15-18, 23-15-23, 23-15-28, 23-16-
38, 23-17-52 and 23-17-54, 23-15-28) were cloned from
proviral DNA not rigorously diluted to endpoint due to
limited amounts of DNA.
Envelope cloning and sequencing
Purified PCR products were cloned into pcDNA™ 3.1D/
V5-His-TOPO
® (pcDNATM3.1 Directional TOPO
®
Expression Kit; Invitrogen Inc). Env+ plasmids were
transformed into competent E. coli (TOP10; Invitrogen
Inc.). Colonies were screened for correct rev-env
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(5’-TAATACGACTCACTATAGGG-3’)a n dM 5 - R( 5 ’-
CCAGCTGGGGCACAATAATGTATGGGAATTGG-3’
(a primer that hybridizes within our insert); [79]) using
Go Taq
® Green Master Mix (Promega Inc.). Plasmid
DNA was purified using QIAprep Miniprep Kit (Qiagen)
and sequenced by Genewiz Inc.
Up to 32 endpoint rev-env clones were sequenced for
each sample and analyzed phylogenetically to establish the
population diversity. Envelope sequences were analyzed
for variation likely to impact on phenotypes e.g. N283,
variable loop length, V1-V2, V3 and V1-V5 loop charge,
PNGSs as well as for mutations likely to render envelopes
non-functional e.g. deletions, premature stop codons, loss
of a conserved cysteine involved in disulphide bonding etc.
Non-functional envelopes with stop codons or deletions
were not included in the analyses.
The nucleotide sequences of novel envelopes reported
here have been assigned GenBank accession numbers
JN786685-JN786871.
Phylogenetic analyses
Complete gp160 env nucleotide sequences were
assembled and aligned using Clustal × [80] with manual
adjustment. All positions with an alignment gap of one
or more nucleotides were excluded.
Phylogenetic and molecular evolutionary analyses were
conducted using MEGA version 5 [81]. Maximum likeli-
hood phylogenetic trees were generated using General
Time Reversible Substitution Model using a discrete
Gamma distribution with 5 rate categories and by assum-
ing that a certain fraction of sites are evolutionary invari-
able for subjects CA110, 7766 and 6568 and without
invariant sites for subjects NA20 and 10017. Bootstrap
analyses on 1,000 replicates was used to assess the robust-
ness of the tree. Significant (≥ 70%) bootstrap values were
assigned to internal tree nodes. Reference sequences
representing three HIV-1 group M subtype B http://www.
hiv.lanl.gov/ envelopes (FR.83. HXBc2. K03455; TH.90.
BK132.AY173951;US.98.1058 11.AY331295) were used as
outgroups.
Cell cultures
293T cells were used to prepare env+ pseudovirions by
transfection. HeLa TZM-bl [82] were used to evaluate
env+ pseudovirion infectivity titers and neutralization.
Pseudovirion infectivity was also evaluated on CD4+
CXCR4+ CCR5- HeLa HIJ cells to monitor CXCR4-use.
HeLa TZM-bl cells express high levels of CD4, CCR5
and CXCR4 and contain HIV-inducible b-galactosidase
and luciferase reporter genes. 293T cells, TZM-bl cells,
and HIJ cells [83], were maintained in Dulbecco’sm o d i -
fied Eagle’s medium (DMEM, Gibco-Invitrogen, Carls-
bad, CA) supplemented with 10% fetal bovine serum
(FBS) and were cultured as previously described
[12,66,68].
Macrophage cultures were prepared from elutriated
monocytes [12,66,68], which were provided by the Univer-
sity of Massachusetts Center for AIDS Research Elutria-
tion Core. The elutriated monocytes were cultured for 5
days in DMEM medium containing 10% human plasma
(HP) for differentiation before setting up for infection.
Alternatively, macrophages were prepared from Ficoll-pur-
ified white blood cells from whole blood by as described
previously [12]. On the day prior to infection, the macro-
phages were washed and resuspended in DMEM medium
containing 10% HP and cultured in 48-well tissue culture
plates (1.25 × 10
5 cells/well/0.5 ml).
Production and infectivity assays of env
+ pseudovirions
Env+ pseudovirions were prepared by cotransfection of
env+ pTOPOenv vector with env- pNL4.3Δenv construct
that carried a premature stop codon in env [12] into 293T
cells using calcium phosphate. Cell free supernatants were
harvested after 48 h culture and frozen at -152°C prior to
experimental analysis.
Env+ pseudovirions were titrated on HeLa TZM-bl cells,
HeLa HIJ cells and on macrophages. For HeLa TZM-bl
and HeLa HIJ cells, 2 × 10
4 cells/0.5 ml were added to
each well on a 48 well plate the day prior to virus titration.
Virus titers were determined as described previously
(Peters 2004, 2006). Briefly, 100 μl of serially diluted viral
supernatants in DMEM media (10% FBS) were added to
cells in duplicate and incubated for 3 hours. 0.4 ml of
DMEM (10% FBS) was added to each well and cultures
incubated for 48 h (Hela TZM-bl) or 72 h (HIJ). TZM-bl
cells were then fixed in 0.5% gluteraldehyde in PBS and b-
galactosidase X-gal substrate added. HeLa HIJ cells were
fixed in cold methanol:acetone 1:1, washed and immunos-
tained for p24 using monoclonal antibodies 38:96K and
EF7 (UK Centre for AIDS Research), followed by an anti-
mouse IgG-b-galactosidase conjugate and X-gal substrate
(0.5 mg/ml X-gal, 3 mM potassium ferrcyanide, 3 mM
potassium ferrocyanide, 1 mM magnesium chloride).
Macrophages were seeded in 48 well plates (1.25 × 10
5
cells/0.5 ml/well) the day prior to infection. Macrophages
were pretreated with 0.1 ml DEAE dextran (10 μg/ml) in
DMEM medium containing 10% HP for 30 min at 37°C
before virus supernatants were added and spinoculating
for 45 minutes in a benchtop centrifuge [84]. Infected
macrophages were incubated for a further 3 h at 37°C
before the addition of 0.4 ml of DMEM (10% HP) and
incubating at 37°C for seven days. Macrophages were then
fixed and immunostained for p24 as described for HIJ
cells. DEAE dextran and spinoculation enhance virus
infectivity by approximately 20-fold by increasing attach-
ment [84] and entry [85]. Infection following this proce-
dure does not bypass the requirement of CD4 and CCR5
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Thus, macrophage infection conferred by envelopes
described here was inhibited by maraviroc (not shown).
Since env
+ p s e u d o v i r i o n sa r ec a p a b l eo fo n l yas i n g l e
round of replication, we were able to estimate the number
of focus-forming units (FFU) by counting individual or
small groups of infected blue-stained cells by light micro-
scopy. Average numbers of FFUs/ml were then calculated.
All values represent the averages of at least two indepen-
dent experiments, each done in duplicate and using
macrophages from different donors. Error bars in figures
were calculated from replicate wells of both experiments.
Each set of macrophage, TZM-bl and HIJ infections
included several control env+ pseudovirions including
NL4.3 (X4), JR-CSF and NA420 LN40 (non-mac-tropic
R5 envelopes), JR-FL and NA420 B33 (mac-tropic R5
envelopes).
Inhibition and neutralization assays
Inhibition and neutralization assays for soluble CD4
(sCD4), maraviroc and mab b12 were carried out in 96
well plates as described previously using HeLa TZM-bl
cells as target cells [52] For maraviroc, cells were treated
with 2-fold dilutions in 50 μl for 30 minutes before add-
ing an equal volume containing 200 FFU of pseudovir-
ions. For sCD4 and b12, 50 μl samples of serially diluted
sCD4 were mixed with 50 μl env+ pseudovirions carry-
ing 200 FFU at 37°C for 1 h and added to HeLa TZM-
bl cells. To evaluate residual infectivity, medium was
removed and 100 μl of medium without phenol red
added. Cells were then fixed and solubilized by adding
100 μl of Beta-Glo (Promega Inc.). Luminescence was
then read in a BioTek Clarity luminometer.
Statistical methods
A robust semiparametric regression model [86] imple-
mented by R package drc [87] was used to model dose
response relationships between the macrophage infectiv-
ity (as a percentage of TZM-bl infectivity) and IC50
concentration of maraviroc, sCD4 and b12. The dosages
that caused 50% inhibition (IC50) were estimated as
well as their 95% confidence intervals (not shown). Two
parameter log-logistic regressions were used for one
envelope, FL11-1-249 for b12 inhibition due to over-fit-
ting of semiparametric approach in the neighbor area of
IC50. When there was no apparent inhibition or inhibi-
tion failed to reach 100%, the model-fitting algorithm
either did not converge or reported an extrapolating
estimate out of the experimental ranges with a very
wide confidence interval. For these inhibitions, the IC50
estimates were winsorized by defining them manually
from Excel plotted graphs. Two tailed, nonparametric
Mann Whitney tests were used to evaluate whether
there exists statistically significant differences between
distributions of IC50s of maraviroc, sCD4 and b12 for
envelopes from brain and from LN/spleen. Two tailed,
non-parametric Spearman tests were used to evaluate
whether there exists monotonic correlation between
macrophage infectivity and IC50s for maraviroc, sCD4
and b12 (Figure 5). Two tailed, nonparametric Mann
Whitney tests were also used to test for significant dif-
ferences in V1-V5 positive charge, length and number
of potential N-linked PNGSs sites. These tests were car-
ried out using Graphpad Prism 5 for Mac OSX.
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